Levi Strauss & Co. vs GeneDx Holdings Corp — how do they compare? Levi Strauss & Co. trades at $24.55 (market cap $9.21B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Levi Strauss & Co. is far larger — about 5.1× GeneDx Holdings Corp's market cap, and Levi Strauss & Co. pays a 2.68% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| LEVI | WGS | |
|---|---|---|
Market Cap | $9.21B | $1.80B |
Sector | Consumer Cyclical | Technology |
52-Week High | $24.99 | $167.51 |
52-Week Low | $17.92 | $34.51 |
Enterprise Value | $10.52B | $1.80B |
Dividend Yield | 2.68% | — |
Signals from Pluang's Aura AI — not financial advice
Levi Strauss & Co. (LEVI) trades at $24.56, up 0.82% on the day, with strong analyst support (83% Buy rating) and a consensus price target of $28.00. Recent quarterly earnings have consistently beaten expectations, including a Q2 2026 EPS of $0.28 versus $0.24 expected, driven by robust direct-to-consumer growth. The company maintains solid profitability with a 61.72% gross margin and 9.66% net margin, while technical indicators show a bearish overall signal despite bullish moving averages.
The outlook is positive given earnings momentum and raised full-year guidance, though near-term stock performance faces headwinds from tariff concerns and foreign exchange pressures. Investment appeal lies in its digital strategy execution and dividend growth, with risks including competitive pressures and macroeconomic volatility affecting consumer spending.
No Aura AI signal available yet.
Trailing returns across standard periods
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →